First-in-class glycomedicine platform (MIIST) with a $121M BARDA contract funding development of an oral, gut-restricted drug for both gastrointestinal acute radiation syndrome (GI-ARS) and ulcerative colitis (UC). Synedgen’s wedge is a novel, non-systemic multivalent innate-immune signaling target that repairs GI injury via mucosal biology rather than systemic immunosuppression; the same molecule (MIIST305) advances through a single Phase 1 in healthy volunteers that reads out for both indications, and the U.S. government is paying for the ARS half.
Validation as of the 2025-10-29 annual meeting: the BARDA contract has grown to $121M total value (up from $101.2M via a $1.9M modification), with the $16.9M base 47% utilized and six option tranches ahead. The company is cash-flow positive (Q3 2025 profit of $380K, cash balance $3.2M, doubled from year-end 2024) with no capital needs for 2–3 years. A May 2025 409A marked equity at $56M ($2.66/share, up from $0.69). StoryHouse invested $400K on a $25M-cap SAFE with a 20% discount out of Fund I, alongside lead Hal Olin ($1M) and BioSTAR West; SH holds board observation rights.
Ulcerative colitis is the primary commercial prize — a large, growing chronic-disease market where existing biologics carry systemic-immunosuppression baggage that a gut-restricted small molecule can sidestep. GI-ARS is a smaller, government-underwritten market where no FDA-approved countermeasure exists Web; strategic value comes from BARDA-funded stockpile procurement rather than commercial launch dynamics.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Synedgen (MIIST305) | Oral, gut-restricted, non-systemic multivalent innate-immune signaling target for UC + GI-ARS | Seed extension, $25M SAFE cap; $121M BARDA Internal | — |
| Abivax (obefazimod) | Oral first-in-class UC therapy | Public; Phase III readout summer 2025 Web | Synedgen is earlier stage but non-systemic; Abivax is the leading late-stage oral |
| Morphic (MORF-057) | Oral α4β7 integrin inhibitor for UC/Crohn's | Acquired by Lilly for $3.2B, Sept 2024 Web | Different MoA; Morphic exit validates oral-UC strategic appetite |
| Landos (NX-13) | First-in-class UC/Crohn's asset | Acquired by AbbVie, $137.5M upfront + $75M milestones, May 2024 Web | Comparable pre-clinical exit precedent |
| GI-ARS incumbents | No FDA-approved GI-ARS countermeasure exists | — Web | Uncontested category on the ARS side; BARDA selected MIIST305 |
Moat: a novel MoA on a proprietary multivalent chemistry platform, a decade of NIH/BARDA relationships, and an in-house manufacturing facility in Claremont (20–40 kg/yr capacity, per the 2024-05-16 note) supplying drug substance for a highly regulated program.
Likely acquirers are large pharma with IBD franchises: AbbVie (Landos + Celsius acquisitions in 2024) and Lilly (Morphic, $3.2B in Sept 2024) have shown appetite for first-in-class oral UC assets Web. Founders have previously engaged Japanese pharma (e.g. Mitsubishi) and cite strong Japanese interest (Internal, 2024-05-16 note). Realistic exit window opens after Phase 1 human data (expected 2026–2027 per the 2025-10-29 note timeline). Return math at a $25M cap SAFE is materially favorable against the current $56M 409A alone, before any Phase 1 revaluation.
Synedgen annual shareholder meeting run by Kenton Gregory. Board election of Sandy Wiesman (replacing husband Bill) passed over abstentions; several SAFE investors, including Hal Olin, pushed back on board composition changes made without SAFE-investor notice. Q3 2025 profit of $380K, cash doubled to $3.2M, no capital need for 2–3 years. BARDA contract now $121M ($16.9M base, 47% utilized). Initial efficacy studies missed 30% survival-benefit target; two Type C FDA meetings planned in 2026.
Annual Meeting Formalities & Board Election. Quorum established with 63% of outstanding shares (7.1M of 11.3M). Breakdown: 6.2M common, 1.6M Series B preferred, 3.5M Series C preferred. Board election for Sandy Wiesman replacing husband Bill; other directors are Kenton Gregory, Andrew Miller, and Hal Olin. Several shareholders abstained citing concerns about Sandy’s qualifications; motion carried.
Shareholder Concerns & Board Changes. Major pushback on prior board composition changes — three pharmaceutical executives with significant company experience were removed, leaving a 4-person board with concerns about Sandy Wiesman lacking a science/business background. Hal Olin raised Kenton’s "secret planning" issues: board changes went into effect and were made without informing SAFE investors before they invested; Hal invested $1M without knowledge of the planned changes. Matthew (StoryHouse) requested board observation rights/data: the $400K SAFE grants board observation rights but SH has not received board-meeting information despite multiple meetings since investment.
BARDA Contract Overview. Total contract value $121M (up from $101.2M with recent $1.9M modification). Base contract $16.9M, 47% utilized to date. Focus: GI platform for acute radiation syndrome treatment. Six option tranches available for future work. Timeline extended 13 months into 2026 due to expanded scope requirements. No current capital needs for 2–3 years with government funding.
Scientific Progress. Completed four studies in mouse and nano-pig models. Key challenge: initial efficacy studies did not meet 30% survival-benefit target — historical data suggests achievable but optimization needed; euthanasia criteria (35% vs 30% weight-loss thresholds) affecting results. Nano-pig model development critical for FDA animal-rule licensure (replaces nonhuman primate studies). Two runs completed, one ongoing, one more in early 2026. Manufacturing: 8 drug-substance batches and 4 drug-product batches completed.
Financial Performance. Q3 2025 profit $380K, cash-flow positive. Cash balance $3.2M (doubled from $1.6M year-end). Expected 2026 cash $4.4M with revenue timing shifts. NOL and R&D tax credits available for future earnings offset.
Valuation Update. New 409A valuation completed May 2025 at $2.66/share (up from $0.69); total equity value $56M. Assumptions: BARDA base plus options, US commercial GI-mucositis opportunity ($69M NPV potential), partnership scenarios, conservative stockpile purchase assumptions.
Business Development. Primary focus GI-platform commercialization. Target: GI mucositis from chemotherapy/radiation (high unmet need, ~$69M NPV). BD strategy for GI partnerships due to board by end of year. Vista Apex partnership: acquired Periosciences, product relaunch early 2026; guaranteed minimum royalties $1M over license life; Synedgen supplying API with annual minimums.
Risks & Next Steps. Scientific: nano-pig FDA acceptance; dose translation under animal rule; statistical significance in efficacy studies. Business: timeline delays affecting option triggers; US government funding uncertainties; key-personnel retention with small 13-person team. Two FDA Type C meetings planned for 2026 to review model data; commercial strategy development ongoing with BARDA data integration.
Post-close call: Synedgen was awarded the BARDA contract with a $16.9M base period (including 5% fee), removing the need for another SAFE. Base period is mouse studies at two sites; milestone 2 is mini-pig phased studies with GI-tract focus; part three shows changes in the soft model, then FDA sign-off on the two animal species.
Awarded the contract: $16.9M award including a 5% fee, so they don’t need to raise another SAFE as a result. Base period is based on mouse studies at two sites; that type of data is sufficient. Milestone 2 is taking the mini-pig, doing a set of phased studies, and keeping the GI-tract focus. Part three of the grant is showing they’re seeing some changes in their soft model; then take it to the FDA, and the FDA would have to agree that these two animal species are going to be okay with the FDA.
Late-stage diligence call with Josh, Matt, and the Synedgen team on BARDA progress, timing, budget cuts, and cap-table cleanup. BARDA had asked to remove the pig portion, dropping headline value to ~$120M; the year-one budget landed near $14.5M. Timeline for funding was mid-September. Fundraising: Hal at $1M, other HNWs; enough runway with what they have.
BARDA. Submitted two rounds back — this is the scoping part. They asked to take the pig part out which moved the total down to $120M; this year’s budget closer to $10–15M and came in around $14.5M for a year of activity, hoping to hear back and that the technical part of the negotiation is done. BARDA said no-fee contract, but the team is pushing back hard on this — negotiating for a fee above and beyond indirect. Expect updates within the next week.
Runway. Need about $2M to cover 2 years of everything excluding the fee they hope to get and items the contract wouldn’t fund. Fundraising: Hal at $1M plus a few other HNWs; enough to go forward with what they have. Speaking with HMC Inc next week, Michael B, Michael Schlifer from Splim, and Dynasil (public). Another gov grant hearing back on Sept 9 — very sure about this.
Cap table. Bill retired, not engaged; Ken very engaged (especially on BARDA); neither has put in significant capital. Working to get Shenda and Kaveri optioned up, plus the Millers.
Mykito / chitosan context. Europe doesn’t like animal products — a fungal-source product could be helpful; talked to Mykito a few years ago. Can obtain chitosan at $500/kg but not pharma-grade; team cleans it up themselves. Big boom coming for chitosan; Belgian company already has a fungal-source variant.
Signal: Michael B and wife wanted info on the SAFE after a positive conversation.
2024-04-23 intro from Jim Sterling (Missouri University of Science & Technology; formerly KGI) referencing Shenda Baker — Jim previously partnered with Synedgen via Synexofi (Multiple Sclerosis mouse-model studies at Jennifer Hernandez’ lab, KGI) and flagged Synedgen as at an "inflection point" for institutional investment. Source: Meeting Notes recRTIL913LShg50U.